David Goel

Background

David E. Goel (born c. 1971) is the co-founder and Managing General Partner of Matrix Capital Management, a long/short equity hedge fund he co-founded in 1999 ¹. He was born in Toronto, Ontario, Canada, and became a naturalized U.S. citizen in 2013 ². He was the first in his family to attend college ³.

Goel attended Phillips Exeter Academy, graduating in 1989, then enrolled at Harvard University, where he studied government and graduated magna cum laude with a Bachelor of Arts in 1993 ^{1 2}. At Harvard he participated in the Business Club, the Canadian Club, the Pre-Law Society, and the Speech and Parliamentary Debate Society ².

After college, Goel joined Morgan Stanley as a financial analyst in its High Technology Investment Banking division (1993–1995) ². From 1995 to 1996 he worked as a financial analyst at General Atlantic Partners, a large-cap private equity firm ². In 1996 he left General Atlantic to join Tiger Management as a technology research analyst under Julian Robertson, where he spent approximately three years and earned recognition as a “Tiger Cub” through mentorship in fundamental analysis and concentrated portfolio strategy ².

In 1999, Goel co-founded Matrix Capital Management Company, LP in Waltham, Massachusetts with Paul J. Ferri ^{1 4}. He served as principal owner and Managing General Partner with ultimate authority over all investment decisions and business affairs ⁴. Under his leadership, Matrix grew from inception to approximately $11 billion in AUM by 2024 ⁵. The firm achieved largely double-digit annual returns since inception, including a reported 56% return in the first 10 months of 2013 driven by concentrated positions in technology stocks such as Netflix and Workday ². Three-year annualized returns of approximately 38% were reported through mid-2024 ². In August 2024, Goel announced he would be closing Matrix Capital Management due to personal health concerns, returning client capital after 25 years of operation ^{4 5}.

Beyond investing, Goel serves on several boards. He is a member of the Harvard Medical School Board of Fellows, the Harvard Corporation Committee on Finance, the Board of Trustees of the American Repertory Theater at Harvard University, the Harvard Quantum Initiative Founders Group, and the Advisory Council of Harvard Kennedy School’s Mossavar-Rahmani Center for Business and Government ². He previously served as a director of Adaptive Biotechnologies Corp. (through March 2021) and of Zentalis Pharmaceuticals ⁶. He also served as a director of Popular, Inc. (banking services), Univision Communications, and Univision Holdings ⁶. In 2019, Goel and his wife Stacey donated $100 million to Harvard University to enable the relocation of the American Repertory Theater to Allston and to create the David E. and Stacey L. Goel Center for Creativity and Performance ³.

Stated Thesis

Goel publicly described Matrix Capital Management’s approach as fundamentals-focused, bottom-up growth investing with long-term holding periods. In the firm’s ADV filings, Matrix describes itself as making “concentrated portfolio of long and short positions” using “fundamental bottom-up analysis to assess a company’s intrinsic value” ⁶.

Matrix Capital’s stated focus as articulated in public materials is on “U.S. companies focused on semiconductors, software, generative artificial intelligence, machine learning, neural networks, and the technology convergence in life sciences” ⁷. The firm maintained a concentrated portfolio, typically 10–20 core holdings, to emphasize high-conviction positions ⁷.

Goel has characterized his investment time horizon as long-term, stating “I think in 10-year terms” when evaluating portfolio performance ².

On cloud computing, Goel stated that his early 2012 investments in cloud software companies were predicated on “the disruptive power of cloud computing across the technology universe” ⁸.

This section reflects Goel’s self-reported framing of Matrix Capital’s strategy.

Inferred Thesis

Based on verified portfolio data — 13F public equity filings and documented private/growth-stage investments — the following patterns emerge. Note that Matrix operated two distinct vehicles: the hedge fund (primarily public equities) and AyurMaya Capital Management (a private equity affiliate, solely owned and controlled by Goel, focused on life sciences) ⁹. The analysis below covers both.

Portfolio sample: 18 verified investments across both vehicles (the public 13F portfolio at peak was ~23 positions in Q2 2024; private investments include ~8 confirmed companies across Goel’s career).

Sector breakdown (combined verified investments):

Matrix’s public portfolio was technology-heavy through approximately 2023, with major positions in cloud software (Workday, Netflix, Alteryx), semiconductors (GlobalFoundries, NVIDIA), and identity/security (ForgeRock, CrowdStrike). Beginning in 2021–2022, the portfolio shifted substantially toward life sciences. By Q4 2025, the 13F portfolio held only 2 positions, both in biotech (Aura Biosciences 65.5%, Maze Therapeutics 34.5%) ¹⁰. The AyurMaya affiliate focused exclusively on private life sciences: gene therapy (ElevateBio, Encoded Therapeutics), immunology (Acelyrin), RNA delivery (ReCode Therapeutics), and dermatology/inflammation (Endeavor BioMedicines) ¹¹.

Rough sector breakdown across 18+ verified positions spanning the full career: - Technology/Software/Cloud: approximately 9 of 18 verified investments (50%) - Life Sciences/Biotech/Therapeutics: approximately 9 of 18 verified investments (50%)

However, by AUM weight in later years (2021–2024), life sciences increasingly dominated both the hedge fund and the private fund.

Stage distribution: Matrix operated as a growth/late-stage and public-markets investor. Average startup age at investment was approximately 7 years, and average valuation at investment was approximately $262M ¹². The AyurMaya private fund invested in Series A through Series D rounds.

Geographic focus: Predominantly U.S. companies. Of 40 total Tracxn-counted investments, approximately 34 were U.S.-based and 3 were in New Zealand (Xero) ¹².

Check sizes: Matrix committed $48–$108 million in documented private rounds. The hedge fund routinely built positions worth hundreds of millions in public equities. AyurMaya led or co-led rounds ranging from $115 million (Maze Therapeutics Series D) to $401 million (ElevateBio Series D) ^{13 14}.

Investment frequency: At peak (2021), Matrix and AyurMaya together were completing approximately 1.6 new investments per year ¹².

Notable pattern not in stated thesis: The shift from technology toward life sciences was substantial and accelerating in Goel’s final years. While Matrix publicly described its focus as “technology convergence in life sciences,” the actual late-career portfolio was dominated by pure-play biotech therapeutics (Zentalis, Maze, AURA, Encoded, Acelyrin, ElevateBio, ReCode), with technology investments largely exited. The closing 13F shows zero technology holdings.

Co-investor patterns: Goel frequently co-invested alongside Valar Ventures (Xero), Tiger Management (Adaptive Biotechnologies), ARCH Venture Partners and Illumina Ventures (Encoded Therapeutics), Pfizer Ventures and EcoR1 Capital (ReCode Therapeutics), Frazier Life Sciences and Deep Track Capital (Maze Therapeutics) ^{15 16 17 18}.

Portfolio

Public Holdings (13F, as of December 31, 2025)

Note: At peak (Q2 2024), Matrix held approximately 23 public positions totaling $13.1 billion, including large positions in NVIDIA, Alteryx, GlobalFoundries, Zentalis Pharmaceuticals, and Perimeter Solutions. By Q4 2025, after Goel announced the fund’s closure, the portfolio had contracted to 2 remaining positions worth $57.6 million.

Selected Historical Public Holdings

Private / Growth-Stage Investments

Note: Total investments per Tracxn: approximately 40. This table represents approximately 35% of known investments; many public equity positions from the hedge fund’s 25-year history are not individually documented in this table due to limited historical 13F source data.

In Their Own Words

On cloud computing as a transformative force (announcing Xero investment, November 2012): “We have witnessed the disruptive power of cloud computing across the technology universe.” — David E. Goel, Managing Member of Matrix Capital Management, CPA Practice Advisor, November 2012 ⁸

On Xero’s competitive position (November 2012): “Xero differentiates itself, not only as a model for accountancy, but also as a harbinger for where all software companies will have to go if they want to remain relevant.” — David E. Goel, CPA Practice Advisor, November 2012 ⁸

On Xero’s market opportunity (October 2013): “Xero is emerging as the definitive software platform for small business worldwide. Capturing the power and affordability of cloud-based computing, Xero has democratized accounting, payroll, and other business software that was once the privilege of only the largest companies.” — David E. Goel, CPA Practice Advisor, October 2013 ²³

On Adaptive Biotechnologies’ platform (May 2015): “Adaptive has ingeniously combined the vast power of next generation sequencing, distributed computing, and data analytics with proprietary chemistries to create the industry leading immunosequencing platform that enables a portfolio of innovative applications addressing the research, clinical and therapeutic development markets.” — David E. Goel, Managing General Partner, Matrix Capital Management, PR Newswire press release, May 2015 ¹⁵

On long-term investment time horizon: “I think in 10-year terms.” — David E. Goel, as quoted in Alchetron biographical profile ²

On Harvard’s transformative impact and giving (February 2019): “conviction in the value and meaning of giving. Harvard has had a profoundly transformative impact on our lives.” — David E. Goel, Harvard Gazette, February 2019 ³

On the arts center project: “There’s something almost metaphorically perfect about the architectural license to build a center for the arts at the nucleus of Harvard’s expanding campus.” — David E. Goel, Harvard Gazette, February 2019 ³

On innovation and humanitarian goals (June 2024): Matrix Capital Co-Founder and General Managing Partner Goel shared remarks at the Aurora Prize Humanitarian Forum on “how innovation should drive increased gains to humanity through compassionate corporate social responsibility.” — Aurora Humanitarian Initiative, June 2024 ²⁷

What Founders Say

No independently sourced founder testimonials found. Goel was not known as an early-stage venture investor; his investments were predominantly in growth and public-stage companies where founder relationships are less publicly documented. No founder testimonials about working with Goel or Matrix Capital could be independently verified through web searches.

Sources